Home › Ependymoma
Pag-aaral pangklinika para sa Ependymoma na nagre-recruit sa U.S.
15 pag-aaral para sa Ependymoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
Ayos sa estado
- California3 pag-aaral
- District of Columbia3 pag-aaral
- Maryland3 pag-aaral
- Massachusetts3 pag-aaral
- Pennsylvania3 pag-aaral
- Texas3 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Nagre-recruitPhase 2
Edad 12 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT04374305LET Optimized IMPT in Treating Pediatric Patients With Ependymoma
Nagre-recruitPhase 1
Hanggang edad 22 · Lahat ng kasarian · Na-update Nob 10, 2026 · NCT03750513PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Nagre-recruitPhase 1/2
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT06161519Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT07628647Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Nagre-recruitPhase 1
Edad 3 hanggang 25 · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT05106296Natural History Study of Patients With Neurofibromatosis Type 2
Nagre-recruitObservasyonal na pag-aaral
Edad 8 hanggang 75 · Lahat ng kasarian · Na-update Okt 16, 2026 · NCT00598351Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
Nagre-recruitPhase 1
Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Okt 13, 2026 · NCT06193759Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Nagre-recruitPhase 2
Hanggang edad 19 · Lahat ng kasarian · Na-update Okt 13, 2026 · NCT01356290Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma
Nagre-recruitPhase 1
Edad 6 hanggang 21 · Lahat ng kasarian · Na-update Set 11, 2026 · NCT07061626HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Nagre-recruitPhase 1
36 Months – 22 Years · Lahat ng kasarian · Na-update Set 4, 2026 · NCT03911388B7-H3.CD28Z.CART in CNS Neoplasms
Nagre-recruitPhase 1
Edad 2 hanggang 21 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT07390539Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
Nagre-recruit
12 Months – 39 Years · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT05057702Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nagre-recruitPhase 1/2
Edad 4 hanggang 39 · Lahat ng kasarian · Na-update Hul 20, 2026 · NCT05278208ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
Nagre-recruitPhase 1
Edad 2 hanggang 21 · Lahat ng kasarian · Na-update Hun 11, 2026 · NCT04732065Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Nagre-recruitPhase 1
Edad 1 hanggang 26 · Lahat ng kasarian · Na-update Abr 13, 2026 · NCT04185038Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.